	US 11,939,387 B2
	Anti-human interleukin-4 receptor alpha antibody and preparation method and application thereof
Chenghai Zhang, Shanghai (CN); Jinlin Guo, Shanghai (CN); and Yujing Yuan, Shanghai (CN)
Assigned to SHANGHAI MABGEEK BIOTECH. CO., LTD, Shanghai (CN)
Filed by SHANGHAI MABGEEK BIOTECH. CO., LTD., Shanghai (CN)
Filed on Oct. 17, 2022, as Appl. No. 18/047,039.
Application 18/047,039 is a continuation of application No. PCT/CN2021/086806, filed on Apr. 13, 2021.
Claims priority of application No. 202010309238.8 (CN), filed on Apr. 17, 2020.
Prior Publication US 2023/0203172 A1, Jun. 29, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 11/06 (2006.01); C12N 5/16 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01)

CPC C07K 16/2866 (2013.01) [A61K 39/3955 (2013.01); A61P 11/06 (2018.01); C07K 16/2896 (2013.01); C12N 5/16 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2510/02 (2013.01)]

10 Claims

1. An antibody specifically binding to interleukin-4 receptor alpha or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an HCDR1 sequence, an HCDR2 sequence and an HCDR3 sequence, the light chain variable region comprises an LCDR1, an LCDR2 and an LCDR3 sequence, and wherein, the HCDR1 sequence, HCDR2 sequence, HCDR3 sequence, LCDR1 sequence, LCDR2 sequence and LCDR3 sequence respectively comprise the amino acid sequences of SEQ ID NOs: 129-134.